Spotlight -

Drug Development|

Quality Systems

|Videos|May 27, 2023

Discussing Rapid Accurate mRNA Potency Assay Possibilities with Sean Hart

Author(s)Chris Spivey

Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on the topic of rapid accurate mRNA potency assay possibilities.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related Content

CPHI Milan Puts Sustainability to Work, Part 2

BySilvia Forroova

August 14th 2026

What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?

ByZachary Zubulake

August 14th 2026

CPHI Milan Puts Sustainability to Work, Part 1

BySilvia Forroova

August 13th 2026

Based on Manufacturing Intelligence Episode 6, Chris Cole and Richard Jaenisch discuss the risks of using AI in Pharma Development and Manufacturing.

Q&A: AI Coding Tools Carry the Real Risk

ByRichard Jaenisch,Christopher Cole,Zachary Zubulake

August 12th 2026

Sentynl Therapeutics and Mereo BioPharma Group have entered a collaboration to release a new treatment for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)

Alvelestat Deal Signals Early Manufacturing Push for AATD-LD

ByZachary Zubulake

August 12th 2026

Trending on Pharmaceutical Technology

Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.

What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

Danish Biotechs Attracting Investor Attention

Q&A: Why Is Halo Pharma Expanding Into Sterile Injectables Now?